A Measure of Treatment Satisfaction Designed Specifically for People with Insulin‐dependent Diabetes

Lewis, Kathryn S; Bradley, Clare; Knight, Graham; Boulton, Andrew J.M.; Ward, John D.

doi:10.1111/j.1464-5491.1988.tb00976.x

Cited by 81 publications

(49 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Treatment satisfaction was assessed using the validated Diabetes Treatment Satisfaction Questionnaire (DTSQ), completed at baseline, week 12, and month 6 (16,17).…”

Section: Discussionmentioning

confidence: 99%

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)

et al. 2014

View full text Add to dashboard Cite

OBJECTIVETo compare the efficacy and safety of new insulin glargine 300 units/mL (Gla-300) with glargine 100 units/mL (Gla-100) in people with type 2 diabetes on basal insulin ( ‡42 units/day) plus mealtime insulin. RESEARCH DESIGN AND METHODSEDITION 1 (NCT01499082) was a 6-month, multinational, open-label, parallelgroup study. Adults with glycated hemoglobin A 1c (HbA 1c ) 7.0-10.0% (53-86 mmol/mol) were randomized to Gla-300 or Gla-100 once daily with dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L. Primary end point was HbA 1c change from baseline; main secondary end point was percentage of participants with one or more confirmed (£3.9 mmol/L) or severe nocturnal hypoglycemia from week 9 to month 6. RESULTSParticipants (n = 807) had mean age 60 years, diabetes duration 16 years, BMI 36.6 kg/m 2 , and HbA 1c 8.15% (65.6 mmol/mol). HbA 1c reduction was equivalent between regimens; least squares mean difference -0.00% (95% CI -0.11 to 0.11) (-0.00 mmol/mol [-1.2 to 1.2]). Fewer participants reported one or more confirmed (£3.9 mmol/L) or severe nocturnal hypoglycemic events between week 9 and month 6 with Gla-300 (36 vs. 46% with Gla-100; relative risk 0.79 [95% CI 0.67-0.93]; P < 0.005); nocturnal hypoglycemia incidence and event rates were also lower with Gla-300 in the first 8 weeks of treatment. No between-treatment differences in tolerability or safety were identified. CONCLUSIONSGla-300 controls HbA 1c as well as Gla-100 for people with type 2 diabetes treated with basal and mealtime insulin but with consistently less risk of nocturnal hypoglycemia.

show abstract

“…Treatment satisfaction was assessed using the validated Diabetes Treatment Satisfaction Questionnaire (DTSQ), completed at baseline, week 12, and month 6 (16,17).…”

Section: Discussionmentioning

confidence: 99%

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)

et al. 2014

View full text Add to dashboard Cite

show abstract

“…However, we have consulted a number of general and cross-sectional studies to provide an insight to the health status associated with CSII treatment. We have discussed above a number of studies that address issues related to severe hypoglycaemia and QoL and offer brief detail below of studies by Chantelau and colleagues 154 and Lewis and colleagues 155 that considered general QoL issues in the context of CSII. However, these studies are not randomised or crossover designs, and the quality of the studies (often descriptive in nature) is variable; caution should be exercised in the interpretation and generalisation of any findings.…”

Section: Csii Versus Mdi: Quality Of Life Assessmentmentioning

confidence: 99%

Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes

Colquitt¹,

Green²,

Sidhu³

et al. 2004

Health Technol Assess

106

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents, York Publishing Services by:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to York Publishing Distribution and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.ncchta.org/htacd.htm). Or contact York Publishing Services (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.The HTA programme commissions research only on topics where it has identified key gaps in the evidence needed by the NHS. Suggestions for topics are actively sought from people working in the NHS, the public, consumer groups and professional bodies such as Royal Colleges and NHS Trusts.Research suggestions are carefully considered by panels of independent experts (including consumers) whose advice results in a ranked list of recommended research priorities. The HTA Programme then...

show abstract

“…Satisfaction with treatment and perception of occurrence of hypo-and hyperglycemia were assessed with the Diabetes Treatment Satisfaction Questionnaire (DTSQ), and health-related quality of life was assessed with the EQ-5D (13,14). Behaviors and worries related to hypoglycemia were assessed with the HFS II (15).…”

Section: Measurements and Biochemical Analysesmentioning

confidence: 99%

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)

et al. 2015

View full text Add to dashboard Cite

OBJECTIVEInsulin therapy in type 1 diabetes still provides suboptimal outcomes. Insulin glargine 300 units/mL (Gla-300), with a flatter pharmacodynamic profile compared with insulin glargine 100 units/mL (Gla-100), is an approach to this problem. RESEARCH DESIGN AND METHODSPeople with type 1 diabetes, using a mealtime and basal insulin regimen, were randomized open-label to Gla-300 or Gla-100 and to morning or evening injection, continuing the mealtime analog, and followed for 6 months. RESULTSParticipants (n = 549) were a mean age of 47 years and had a mean duration of diabetes of 21 years and BMI of 27.6 kg/m 2 . The change in HbA 1c (primary end point; baseline 8.1%) was equivalent in the two treatment groups (difference, 0.04% [95% CI 20.10 to 0.19]) (0.4 mmol/mol [21.1 to 2.1]), and Gla-300 was thus noninferior. Similar results with wider 95% CIs were found for morning and evening injection times and for prebreakfast self-measured plasma glucose (SMPG) overall. Results were also similar for Gla-300 when morning and evening injection time was compared, including overlapping 8-point SMPG profiles. Hypoglycemia did not differ, except for the first 8 weeks of the study, when nocturnal confirmed or severe hypoglycemia was lower with Gla-300 (rate ratio 0.69 [95% CI 0.53-0.91]). Hypoglycemia with Gla-300 did not differ by time of injection. The basal insulin dose was somewhat higher at 6 months for Gla-300. The adverse event profile did not differ and was independent of the Gla-300 time of injection. Weight gain was lower with Gla-300. CONCLUSIONSIn long-duration type 1 diabetes, Gla-300 provides similar glucose control to Gla-100, with a lower risk of hypoglycemia after transfer from other insulins, independent of time of injection, and less weight gain.Type 1 diabetes requires life-long insulin therapy, with consequences for quality of life (1). Accordingly, insulin administration should be convenient and support selfmanagement by being adaptable to individual lifestyle. Current recommendations are generally basal plus mealtime insulin injections with insulin analogs, or pump

show abstract

A Measure of Treatment Satisfaction Designed Specifically for People with Insulin‐dependent Diabetes

Cited by 81 publications

References 12 publications

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)

Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)

Contact Info

Product

Resources

About